Lung defenses

Dail and Hammar's Pulmonary Pathology

Volumn 1, Issue , 2008, Pages 49-63

  Kobzik, Les ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953105302     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-68792-6_3     Document Type: Chapter

References (130)

1. McClellan R. Particle interactions in the respiratory tract. In: P Gehr, 1 Heyder, eds. Particle-lung interactions. New York: Marcel Dekker, 2000:366.
2. Bogaert D, De Groot R, Hermans pw. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004;4:144-154.
3. Gleeson K, Eggli DF, Maxwell, SL. Quantitative aspiration during sleep in normal subjects. Chest 1997;111:1266-1272.
4. Sessa R, Di PM, Schiavoni G, et al. Microbiological indoor air quality in healthy buildings. New Microbiol 2002;25: 51-56.
5. Riley RL. Aerial dissemination of pulmonary tuberculosis. Am Rev Tuberc 1957;76:931-941.
6. Bell ML, Davis DL, Fletcher T. A retrospective assessment of mortality from the London smog episode of 1952: the role of influenza and pollution. Environ Health Perspect 2004;112:6-8.
7. Stone R. Air pollution. Counting the cost of London's killer smog. Science 2002;298:2106-2107.
8. Nel A. Atmosphere. Air pollution-related illness: effects of particles. Science 2005;308:804-806.
9. Donaldson K, Stone V, Seaton A, MacNee W. Ambient particle inhalation and the cardiovascular system: potential mechanisms. Environ Health Perspect 2001;109(suppl 4):523-527.
10. Bernstein lA, Alexis N, Barnes C, et al. Health effects of air pollution. 1 Allergy Clin ImmunoI2004;114:1116-1123.
11. Tao F, Gonzalez-Flecha B, Kobzik L. Reactive oxygen species in pulmonary inflammation by ambient particulates. Free Radic Bioi Med 2003;35:327-340.
12. Oberdorster G. Pulmonary effects of inhaled ultrafine particles. Int Arch Occup Environ Health 2001;74:1-8.
13. Dockery DW, Pope CA 3rd, Xu X, et al. An association between air pollution and mortality in six U.S. cities. N Engl 1 Med 1993;329:1753-1759.
14. Dockery DW, Pope CA 3rd. Acute respiratory effects of particulate air pollution. Annu Rev Public Health 1994;15: 107-132.
15. U.S. Environmental Protection Agency. The ozone report: measuring progress through 2003. Research Triangle Park, NC: EPA, 2004.
16. Last lA, Sun WM, Wits chi H. Ozone, NO, and N02: oxidant air pollutants and more. Environ Health Perspect 1994; 102(suppl10):179-184.
17. American Thoracic Society. Health effects of outdoor air pollution. Am 1 Respir Crit Care Med 1996;153:3-50.
18. Reynolds SM, Mackenzie Al, Spina D, Page CP. The pharmacology of cough. Trends Pharmacol Sci 2004;25:569-576.
19. Marik PE, Kaplan D. Aspiration pneumonia and dysphagia in the elderly. Chest 2003;124:328-336.
20. Reynolds HY. Defense mechanisms against infections. Curr Opin Pulm Med 1999;5:136-142.
21. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. 1 Clin Invest 2002;109:571-577.
22. Ganz T Antimicrobial polypeptides. 1 Leukoc Bioi 2004;75:34-38.
23. Markart P, Korfhagen TR, Weaver TE, Akinbi HT Mouse lysozyme M is important in pulmonary host defense against Klebsiella pneumoniae infection. Am 1 Respir Crit Care Med 2004;169:454-458.
24. Singh PK, Tack BF, McCray PB lr, Welsh MJ. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am 1 Physiol Lung Cell Mol Physiol 2000;279:L799-805.
25. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev ImmunoI2003;3:710-720.
26. Zanetti M. Cathelicidins, multifunctional pep tides of the innate immunity. 1 Leukoc Bioi 2004;75:39-48.
27. Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir 1 2004;23:327-333.
28. Moser C, Weiner Dl, Lysenko E, Bals R, Weiser lN, Wilson 1M. Beta-Defensin 1 contributes to pulmonary innate immunity in mice. Infect Immun 2002;70:3068-3072.
29. Bals R, Weiner Dl, Meegalla RL, Wilson 1M. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. 1 Clin Invest 1999;103:1113-1117.
30. Hickling TP, Clark H, Malhotra R, Sim RB. Collectins and their role in lung immunity. 1 Leukoc Bioi 2004;75: 27-33.
31. Wu H, Kuzmenko A, Wan S, et al. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. 1 Clin Invest 2003;111: 1589-1602.
32. LeVine AM, Kurak KE, Bruno MD, Stark 1M, Whitsett lA, Korfhagen TR. Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am 1 Respir Cell Mol Bioi 1998;19:700-708.
33. LeVine AM, Bruno MD, Huelsman KM, Ross GF, Whitsett lA, Korfhagen TR. Surfactant protein A-deficient mice are susceptible to group B streptococcal infection. 1 lmmunol 1997;158:4336-4340.
34. LeVine AM, Hartshorn K, Elliott 1, Whitsett 1, Korfhagen TAbsence of SP-A modulates innate and adaptive defense responses to pulmonary influenza infection. Am 1 Physiol Lung Cell Mol PhysioI200 2; 282: L563-572.
35. LeVine AM, Whitsett lA, Hartshorn KL, Crouch EC, Korfhagen TR. Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. 1 Immunol2001;167: 5868-5873.
36. LeVine AM, Whitsett lA, Gwozdz lA, et al. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. 1 Immunol 2000;165:3934-3940.
37. Wright lR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005;5:58-68.
38. Gross GN, Rehm SR, Pierce AK. The effect of complement depletion on lung clearance of bacteria. 1 Clin Invest 1978;62:373-378.
39. Hopken UE, Lu B, Gerard NP, Gerard C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 1996;383:86-89.
40. Mueller-Ortiz SL, Drouin SM, Wetsel RA. The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia. Infect Immun 2004;72:2899-2906.
41. lackson LA, Neuzil KM, Yu 0, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl 1 Med 2003;348:1747-1755.
42. Cunningham-Rundles C. Physiology of IgA and IgA deficiency. l Clin ImmunoI2001;21:303-309.
43. Pryor WA, Squadrito GL, Friedman M. A new mechanism for the toxicity of ozone. Toxicol Lett 1995;82-83:287-293.
44. Postlethwait EM, Langford SD, Bidani A. Reactive absorption of nitrogen dioxide by pulmonary epithelial lining fluid. 1 Appl Physiol 1990;69:523-531.
45. Cross CE, van der Vliet A, O'Neill CA, Louie S, Halliwell B. Oxidants, antioxidants, and respiratory tract lining fluids. Environ Health Perspect 1994;102(suppI1O):185-191.
46. Comhair SA, Erzurum Sc. Antioxidant responses to oxidant-mediated lung diseases. Am 1 Physiol Lung Cell Mol Physiol 2002;283:L246-255.
47. Frampton MW, Morrow PE, Torres A, Cox C, Voter KZ, Utell MJ. Ozone responsiveness in smokers and nonsmokers. Am 1 Respir Crit Care Med 1997;155:116-121.
48. MacNee W. Oxidants/antioxidants and COPD. Chest 2000; 117: 303S-317S.
49. Norwood 1 lr, Ledbetter AD, Doerfler DL, Hatch GE. Residual oil fly ash inhalation in guinea pigs: influence of absorb ate and glutathione depletion. Toxicol Sci 2001;61: 144-153.
50. Kodavanti Up, Costa DL, Richards 1, Crissman KM, Slade R, Hatch GE. Antioxidants in bronchoalveolar lavage fluid cells isolated from ozone-exposed normal and ascorbatedeficient guinea pigs. Exp Lung Res 1996;22:435-448.
51. Carlsson LM, 10nsson 1, Edlund T, Marklund SL. MicIC lacking extracellular superoxide dismutase are more sensitive to hyperoxia. Proc Natl Acad Sci USA 1995;92: 6264-6268.
52. Folz Rl, Abushamaa AM, Suliman HB. Extracellular superoxide dismutase in the airways of transgenic mice reduces inflammation and attenuates lung toxicity following hyperoxia. 1 Clin Invest 1999;103:1055-1066.
53. Ho YS. Transgenic and knockout models for studying the role of lung antioxidant enzymes in defense against hyperoxia. Am 1 Respir Crit Care Med 2002;166:S51-56.
54. Crapo LD, Young SL, Fram EK, Pinkerton KE, Barry BE, Crapo Ro. Morphometric characteristics of cells in the alveolar region of mammalian lungs. Am Rev Respir Dis 1983;128:S42-46.
55. Reynolds HY. Immunologic system in the respiratory tract. Physiol Rev 1991;71:1117-1133.
56. van oud Alblas AB, van Furth R. Origin, kinetics, and characteristics of pulmonary macrophages in the normal steady state. J Exp Med 1979;149:1504-1518.
57. Thomas ED, Ramberg RE, Sale GE, Sparkes RS, Golde DW. Direct evidence for a bone marrow origin of the alveolar macrophage in man. Science 1976;192:1016-1018.
58. Green GM, Kass EH. The role of the alveolar macrophage in the clearance of bacteria from the lung. J Exp Med 1964;119:167-176.
59. Jonsson S, Musher, DM, Chapman A, Goree A, Lawrence EC Phagocytosis and killing of common bacterial pathogens of the lung by human alveolar macrophages. J Infect Dis 1985;152:4-13.
60. Dockrell DH, Marriott HM, Prince LR, et a!. Alveolar macrophage apoptosis contributes to pneumococcal clearance in a resolving model of pulmonary infection. J Immunol 2003;171:5380-5388.
61. Broug-Holub E, Toews GB, van Iwaarden JF, et a!. Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect Immun 1997;65:1139-1146.
62. Leemans JC, Juffermans NP, F10rquin S, et a!. Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol 2001;166:4604-4611.
63. Shao X, Mednick A, Alvarez M, van Rooijen N, Casadevall A, Goldman DL. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J ImmunoI2005;175:3244-3251.
64. Janeway CA, Jr, Medzhitov R. Innate immune recognition. Annu Rev ImmunoI2002;20:197-216.
65. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev ImmunoI2005;23:901-944.
66. Krieger M, Acton S, Ashkenas J, Pearson A, Penman M, Resnick D. Molecular flypaper, host defense, and atherosclerosis. Structure, binding properties, and functions of macrophage scavenger receptors. J BioI Chern 1993;268: 4569-4572.
67. Palecanda A, Kobzik L. Receptors for unopsonized particles: the role of alveolar macrophage scavenger receptors. Curr Mol Med 2001;1:589-595.
68. Herre J, Gordon S, Brown GD. Dectin-1 and its role in the recognition of beta-glucans by macrophages. Mol Immunol 2004;40:869-876.
69. Zhang J, Zhu J, Imrich A, Cushion M, Kinane TB, Koziel H. Pneumocystis activates human alveolar macrophage NF-kappaB signaling through mannose receptors. Infect Immun 2004;72:3147-3160.
70. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev ImmunoI2004;4:499-511.
71. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-145.
72. Swanson JA, Hoppe AD. The coordination of signaling during Fc receptor-mediated phagocytosis. J Leukoc BioI 2004;76:1093-1103.
73. Stuart LM, Ezekowitz RA. Phagocytosis: elegant complexity. Immunity 2005;22:539-550.
74. lies KE, Forman HI Macrophage signaling and respiratory burst. Immunol Res 2002;26:95-105.
75. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci USA 2000;97:8841-8848.
76. Fang FC Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2004;2:820-832.
77. Kobzik L, Bredt DS, Lowenstein CJ, et al. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am J Respir Cell Mol BioI 1993;9:371-377.
78. van Straaten JF, Postma DS, Coers W, Noordhoek JA, Kauffman HF, Timens W. Macrophages in lung tissue from patients with pulmonary emphysema express both inducible and endothelial nitric oxide synthase. Mod Pathol 1998;11:648-655.
79. Nicholson S, Bonecini-Almeida M da G, Lapa e Silva JR, et al. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 1996;183:2293-2302.
80. Weinberg JB. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol Med 1998;4:557-591.
81. Fang FC, Vazquez-Torres A. Nitric oxide production by human macrophages: there's NO doubt about it. Am J Physiol Lung Cell Mol Physiol 2002;282:L941-943.
82. Peters-Golden M, Canetti C, Mancuso P, Coffey MI Leukotrienes: under appreciated mediators of innate immune responses. J ImmunoI2005;174:589-594.
83. Zhang P, Summer WR, Bagby GJ, Nelson S. Innate immunity and pulmonary host defense. Immunol Rev 2000;173: 39-51.
84. Pier GB. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc Nat! Acad Sci USA 2000;97: 8822-8828.
85. Diamond G, Legarda D, Ryan LK. The innate immune response of the respiratory epithelium. Immunol Rev 2000;173:27-38.
86. Elias JA, Zheng T, Lee CG, et a!. Transgenic modeling of interleukin-13 in the lung. Chest 2003;123:339S-345S.
87. van der Weyden L, Adams DJ, Bradley A. Tools for targeted manipulation of the mouse genome. Physiol Genomics 2002;11:133-164.
88. Sledz CA, Williams BR. RNA interference in biology and disease. Blood 2005;106:787-794.
89. Segal AW. How neutrophils kill microbes. Annu Rev Immunol 2005;23:197-223.
90. Rosenzweig SD, Holland SM. Phagocyte immunodeficiencies and their infections. J Allergy Clin ImmunoI2004;113: 620-626.
91. Abraham SN, Thankavel K, Malaviya R. Mast cells as modulators of host defense in the lung. Front Biosci 1997;2: d78-87.
92. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat ImmunoI2005;6:135-142.
93. Marshall lS, lawdat DM. Mast cells in innate immunity. 1 Allergy Clin ImmunoI2004;114:21-27.
94. French AR, Yokoyama WM. Natural killer cells and viral infections. CUff Opin Immunol 2003;15:45-51.
95. Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol 2004;22:405-429.
96. Vermaelen K, Pauwels R. Pulmonary dendritic cells. Am 1 Respir Crit Care Med 2005;172:530-551.
97. Lambrecht BN, Hammad H. Taking our breath away: dendritic cells in the pathogenesis of asthma. Nat Rev Immunol 2003;3:994-1003.
98. Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl 1 Med 1995;332:1280-1284.
99. Doherty PC, Topham Dl, Tripp RA, Cardin RD, Brooks lW, Stevenson Po. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997;159:105-117.
100. Cox Rl, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand 1 ImmunoI2004;59:1-15.
101. Openshaw Pl, Tregoning lS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 2005;18:541-555.
102. Buckley RH. Pulmonary complications of primary immunodeficiencies. Paediatr Respir Rev 2004;5(suppl A): S225-233.
103. Kotloff RM, Ahya VN, Crawford Sw. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am 1 Respir Crit Care Med 2004;170: 22-48.
104. Boy ton RL. Infectious lung complications in patients with HIV/AIDS. Curr Opin Pulm Med 2005;11:203-207.
105. Whitney CG, Harper SA. Lower respiratory tract infections: prevention using vaccines. Infect Dis Clin North Am 2004;18:899-917.
106. Williams GT, Williams WL. Granulomatous inflammation-a review. 1 Clin PathoI1983;36:723-733.
107. Perez RL, Rivera-Marrero CA, Roman 1. Pulmonary granulomatous inflammation: From sarcoidosis to tuberculosis. Semin Respir Infect 2003;18:23-32.
108. Mohr LC. Hypersensitivity pneumonitis. CUff Opin Pulm Med 2004;10:401-41I.
109. Sawyer RT, Maier LA, Kittle LA, Newman LS. Chronic beryllium disease: a model interaction between innate and acquired immunity. Int Immunopharmacol 2002;2:249-261.
110. Vignery A. Macrophage fusion: the making of osteoclasts and giant cells. 1 Exp Med 2005;202:337-340.
111. Saginario C, Sterling H, Beckers C, et al. MFR, a putative receptor mediating the fusion of macrophages. Mol Cell BioI 1998;18:6213-6223.
112. Han X, Sterling H, Chen Y, et al. CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. 1 BioI Chern 2000;275:37984-37992.
113. Yagi M, Miyamoto T, Sawatani Y, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. 1 Exp Med 2005;202:345-351.
114. Kaufmann SH. Protection against tuberculosis: cytokines, T cells, and macrophages. Ann Rheum Dis 2002;61(suppl 2):ii54-58.
115. Co DO, Hogan LH, II-Kim S, Sandor M. T cell contributions to the different phases of granuloma formation. Immunol Lett 2004;92:135-142.
116. Mogues T, Goodrich ME, Ryan L, LaCourse R, North R1. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. 1 Exp Med 2001;193:271-280.
117. Barnes PF, Bloch AB, Davidson PT, Snider DE, Jr. Tuberculosis in patients with human immunodeficiency virus infection. N Engl 1 Med 1991;324:1644-1650.
118. Ehrt S, Schnappinger D, Bekiranov S, et al. Reprogramming of the macrophage transcript orne in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. 1 Exp Med 2001;194:1123-1140.
119. Nathan CF, Prendergast Tl, Wiebe ME, et al. Activation of human macrophages. Comparison of other cytokines with interferon-gamma. 1 Exp Med 1984;160:600-605.
120. Newport Ml, Huxley CM, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl 1 Med 1996;335:1941-1949.
121. Turner OC, Basaraba Rl, Orme 1M. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun 2003;71: 864-871.
122. Opie E, Aronson 1. Tubercle bacilli in latent tuberculosis lesions and in lung tissue without tuberculous lesions. Arch Pathol 1927;4:1-21.
123. Lukacs NW, Chensue SW, Strieter RM, Warmington K, Kunkel SL. Inflammatory granuloma formation is mediated by TNF-alpha-inducible intercellular adhesion molecule-I. 1 ImmunoI1994;152:5883-5889.
124. Marshall BG, Wangoo A, Cook HT, Shaw R1. Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis. Thorax 1996;51: 1253-1261.
125. Dheda K, Booth H, Huggett lF, lohnson MA, Zumla A, Rook GA. Lung remodeling in pulmonary tuberculosis. 1 Infect Dis 2005;192:1201-1209.
126. Fallon PG, Richardson El, McKenzie Gl, McKenzie AN. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. 1 Immunol 2000;164:2585-2591.
127. Rhoades ER, Ullrich H1. How to establish a lasting relationship with your host: lessons learned from Mycobacterium spp. Immunol Cell Bioi 2000;78:301-310.
128. Flynn LL., Immune evasion by Mycobacterium tuberculosis: Living with the enemy, Curr Opin Immunol, 2003, 15, 450-455.
129. Zhang P, Bagby GL, Happel KI, Summer WR, Nelson S. Pulmonary host defenses and alcohol. Front Biosci 2002;7: d1314-1330.
130. Drannik AG, Pouladi MA, Robbins CS, Goncharova SI, Kianpour S, Stampfli MR. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am 1 Respir Crit Care Med 2004;170: 1164-1171.